Korro Bio is trading at $14.02, up 5.41%, amid biotech-sector strength.
- XBI is up 2.18% during regular trading; broader market indexes are nearly flat.
- No clear company-specific catalyst for October 28 was identified. KRRO-111 preclinical results were announced October 22, while reported Lynx1 purchases covered earlier dates; neither establishes a direct cause for this session’s rise.
- Trading is live; volume data was not provided.